Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Depression and COPD exacerbation risk

  Depression is common among people living with COPD and can reduce energy, confidence, treatment adherence and participation in pulmonary rehabilitation. These effects may leave a person less able to recognise or manage the early signs of an acute worsening of respiratory symptoms.

  Clinical teams should therefore consider mood symptoms alongside lung function, inhaler technique and exposure to tobacco smoke or air pollution. The association between depression and COPD exacerbation risk is clinically important, although it does not establish that depression alone causes the lung attacks.

  Why mood and lung health belong together

  A COPD exacerbation is an acute worsening of breathlessness, cough or sputum that requires additional treatment. Depression can make symptoms harder to interpret, delay help-seeking and reduce the energy needed for self-management, exercise and recovery after hospital care.

  The relationship runs in both directions. Lung inflammation, frequent exacerbations and disability can worsen depressive mood, while poor mental health can increase isolation, inactivity and medication-related stress. Anxiety and other mental-health conditions often coexist with depression and deserve separate attention.

  What the evidence can and cannot show

  Observational studies link depressive symptoms with more frequent exacerbations, emergency presentations and hospital admissions. Research also suggests that people with depression may have longer stays or more difficulty returning to usual activity after an exacerbation. However, the studies cannot fully separate depression from smoking intensity, socioeconomic hardship, other illnesses or treatment adherence.

  This uncertainty still has a practical message: identify depression early, reassess mood after lung exacerbations and avoid assuming that breathlessness is purely psychological. For conference readers, the APSR 2022 programme offers a broader respiratory-medicine context in which to consider these linked clinical questions.

  Shared pathways that may raise risk

  Smoking is a powerful shared factor. It contributes to COPD and inflammation, limits exercise capacity and is commonly associated with depression and social disadvantage. Depression may in turn make quitting harder by reducing motivation, confidence or the ability to attend cessation support.

  Other pathways include sleep disruption, inactivity, chronic inflammation, medication burden and limited social support. Each can worsen breathing, fatigue and mood. This does not prove that inflammation directly causes depression in every patient, but it explains why integrated care is more useful than treating either condition in isolation.

  Australian conditions that shape the picture

  In Sydney and Melbourne, bushfire smoke can raise fine-particle pollution to harmful levels, increasing respiratory symptoms and potentially precipitating illness in people with COPD. Heat, drought and poorly controlled dust add further burdens, making clean indoor air and checking local air-quality alerts practical parts of self-management.

  The Australian tobacco market is tightly regulated, with plain packaging, substantial taxation and strict retail rules. These measures reduce promotion and support cessation, although nicotine dependence remains a major driver of preventable COPD and can coexist with untreated depression.

  Aboriginal and Torres Strait Islander communities experience disproportionate respiratory burden because of smoking, housing conditions, intergenerational trauma and barriers to timely care. Culturally safe assessment should involve local Aboriginal health services and trusted clinicians rather than a generic depression questionnaire alone.

  Medicare and the Pharmaceutical Benefits Scheme help make GP care and many COPD medicines affordable, but access varies with income, geography and service availability. In regional and remote Australia, telehealth can support review, while limited pulmonary rehabilitation, specialist travel and interrupted medicine supplies make continuity of care especially important.

  Recognising deterioration and mood symptoms

  Depression can be missed because fatigue, sleep problems, breathlessness and reduced exercise tolerance overlap with COPD. A validated tool such as PHQ-2, followed by PHQ-9 when indicated, can support a clinical conversation, although neither score is a diagnosis by itself.

  A brief primary-care screen can ask about:

  • Low mood or loss of pleasure on most days for at least two weeks
  • Changes in sleep, appetite, concentration, energy or self-care
  • Withdrawal from work, family life or pulmonary rehabilitation
  • Thoughts of death, self-harm or a belief that life has no purpose

  Physical and psychiatric deterioration can coexist, so escalation should be explicit:

  • Call 000 for severe breathlessness, chest pain, blue lips or sudden confusion
  • Arrange same-day review for a new or worsening cough, changed sputum or increasing breathlessness
  • Assess suicidal thoughts urgently and involve crisis support, including Lifeline on 13 11 14
  • Review medicines, inhaler technique, oxygen needs and barriers to adherence

  A positive screen should lead to a documented plan, not a referral without follow-up. The clinician should ask what the person is doing, what support is available and whether physical deterioration is also driving the low mood.

  Care that protects lungs and mood

  An exacerbation requires prompt COPD-directed treatment, including short-acting bronchodilators, corticosteroids and antibiotics when clinically indicated. Oxygen assessment and supported smoking cessation belong in the same episode of care. Asking about mood during hospital or urgent review can identify needs that might otherwise remain hidden behind breathlessness.

  After stabilisation, pulmonary rehabilitation is a central intervention. Graded exercise, disease education and peer contact can improve exercise capacity, confidence and depressive symptoms. Psychological therapies such as cognitive behavioural therapy, alongside sleep support and stronger social connection, can complement rehabilitation without replacing it.

  Long-term care should combine a personalised inhaled regimen, vaccination against influenza, pneumococcal disease and COVID-19, and regular inhaler review. Smoking cessation support, quitline access and treatment of anxiety or depression should be coordinated with respiratory follow-up, because each affects the likelihood of another exacerbation.

  A coordinated next step for respiratory care

  Respiratory services are well placed to identify changes in mood, but the strongest response is shared. A care plan can connect the patient’s GP, respiratory clinician, psychologist or pharmacist, rehabilitation team and emergency aftercare, with one current medication list and a clear route for worsening symptoms.

  The next concrete step is a 20-minute GP review that records the PHQ-2 result, smoking status, recent exacerbations and inhaler technique, then issues one written plan covering mood treatment, pulmonary rehabilitation and escalation contacts.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)